Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-18), Canopy Growth's 9-Day RSI is 34.09.
The industry rank for Canopy Growth's 9-Day RSI or its related term are showing as below:
HAM:11L's 9-Day RSI is ranked better than 89.13% of 1049
companies
in the Drug Manufacturers industry
Industry Median: 53.26
vs HAM:11L: 34.09
Canopy Growth (HAM:11L) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Canopy Growth 9-Day RSI Related Terms
HAM:11L vs ZTS, UTHR: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Canopy Growth's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (HAM:11L) has a 9-Day RSI of 34.09 as of Jul. 18, 2026. According to the industry distribution chart, Canopy Growth ranks #114 out of 1049 companies in the Drug Manufacturers industry, placing it in the top 10.9%.
Is Canopy Growth's 9-Day RSI too high?
Canopy Growth's current 9-Day RSI is 34.09. The Drug Manufacturers industry median 9-Day RSI is 53.26. Canopy Growth's value of 34.09 is 36% below this industry median. Based on the distribution chart, Canopy Growth ranks #114 out of 1049 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Canopy Growth has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #114 out of 1049 companies for 9-Day RSI. This places Canopy Growth in the top 11% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 53.26. Canopy Growth's value of 34.09 is 36% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 53.26, based on 1,049 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canopy Growth's current 9-Day RSI of 34.09 is 36% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 53.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current 9-Day RSI is 34.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (HAM:11L) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.63, compared to a current price of €0.81 — trading 27.8% above its estimated fair value. The current 9-Day RSI is 34.09 and 36% below the Drug Manufacturers industry median of 53.26. Canopy Growth's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Canopy Growth (HAM:11L), the current 9-Day RSI is 34.09 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (HAM:11L) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of €0.81 is trading 27.8% above its estimated GF Value™ of €0.63.
GuruFocus considers Canopy Growth to be Modestly Overvalued.
Key valuation signals for HAM:11L:
9-Day RSI: 34.09
GF Value™: €0.63 vs. price of €0.81 (27.8% above fair value)
Industry Position: 36% below the Drug Manufacturers median (#114 of 1049)
No single metric tells the full story. See the HAM:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
59GF Score
Get the complete analysis for HAM:11L
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:11L has been successfully added to your 
